This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

March 18, 2021
Delivered DigitallyCentral European Time

Pan Cancer T


Company Description or Summary : 

Pan Cancer T is a biotech spin-out that builds further on 20 years of pioneering in adoptive cell therapy developed in the laboratory of Tumor Immunology (Erasmus MC, Rotterdam).

We are committed to lead the fight against solid cancers through first-in-class T cell receptor (TCR) gene engineered T-cell therapy.

The company’s approach includes three differentiating elements. First, it exploits unique targets for T-cells that are exclusively expressed by multiple solid cancers. Second, it applies innovative technologies to select naturally occurring and highly specific TCRs with no signs of early exhaustion, and thirdly we develop therapies that overcomes the tumor micro-environmental challenges in the targeted cancers.

Summary of Products, Services or Technologies : 

30 novel intra-cellular targets which are exclusively expressed in solid tumors
Platform to identify and select potent and specific TCR T cells
Platform that allows to immune-profile the hostile tumor micro-environment for the targeted tumors and guide us in the development of modulators
Ability to quickly move into clinic